Autophagy: Novel Action of Panitumumab in Colon Cancer

摘要: Background: Panitumumab, a fully-human monoclonal antibody raised against epidermal growth factor receptor (EGFR), has been approved by the U.S. Food and Drug Administration (FDA) European Medicines Agency (EMEA) for treatment of patients with EGFR- expressing metastatic colorectal carcinoma (mCRC) after failure standard chemotherapy. Additionally, guideline EMEA includes use panitumumab in wild-type KRAS. The goal current study was to evaluate effect on colon cancer cells, proliferation, apoptosis, necrosis, cell cycle arrest autophagy. redox status cells also studied. Materials Methods: lines Caco-2, DLD-1 HT-29 which differ their expression EGFR HER-2 were used. Cell proliferation apoptosis/necrosis measured methyl tetrazolium (MTT) assay annexin V/propidium iodide assay, respectively. estimated propidium autophagy detected using Western blot analysis. Spectrophotometrical quantification glutathione (GSH) levels an analysis KRAS sequence applied. Results: Panitumumab reduced only despite mutated this line. However, did not affect necrosis or progression. Interestingly, immunoblotting revealed that increased protein beclin-1, marker In addition, increase GSH level noted following reflecting imbalance cells. Conclusion: affects independently mutations levels, possibly through induction Among most recent advances management (CRC) are immunotherapies targeting